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WHAT IS ALREADY KNOWN ABOUT
THIS SUBJECT
￿ Transient receptor potential vanilloid
1(TRPV1) receptor antagonists have the
potential to be used in a wide variety of
indications.Whilst many compounds have
been evaluated pre-clinically,published
clinical data are sparse.A possible
dose-limiting effect of TRPV1 antagonists is
their potential to cause hyperthermia.
WHAT THIS STUDY ADDS
￿ This study reports the safety and
pharmacokinetic data for XEN-D0501,a
novel TRPV1 antagonist,in healthy subjects
including effects on body temperature.
AIMS
XEN-D0501,a novel TRPV1 antagonist,is being developed to treat
overactive bladder.This study investigated the safety and
pharmacokinetics of repeat-dose XEN-D0501 in healthy subjects.
METHODS
The study was conducted in two parts.Part 1 was a double-blind,
randomized,placebo-controlled,two-way crossover study in three
cohorts of 12 young male subjects.Each subject received XEN-D0501
and placebo (in random order) twice daily for 13 days,with a ﬁnal
single dose on day 14.Doses of 1,2.5 and 5 mg XEN-D0501 were
investigated.Part 2 was an open-label,randomized,two-way crossover
study in male and female subjects (45 to 65 years).Subjects received
single doses of 5 mg XEN-D0501 under fasted and fed conditions in
random order.Blood sampling and safety assessments were conducted
throughout the study.
RESULTS
XEN-D0501 was rapidly absorbed (tmax generally 0.5–4 h post dose).
XEN-D0501 exposure increased less than proportionally to dose over
the range studied and exhibited minimal accumulation with twice daily
dosing.Food had no clinically relevant effects on the pharmacokinetics
of XEN-D0501.There were no severe or serious adverse events and all
doses were well tolerated.A dose-related increase in body temperature
was seen with XEN-D0501 which attenuated over time.Differences
from placebo in mean maximum core body temperatures were 0.22°C,
0.5°C and 0.74°C following 1 mg,2.5 mg and 5 mg twice daily
XEN-D0501.The observed increase in body temperature was not
considered to be of clinical concern.
CONCLUSIONS
XEN-D0501 appeared safe and well tolerated at doses up to 5 mg twice
daily for 14 days in healthy subjects.
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XEN-D0501 is a potent and selective transient receptor
potential vanilloid 1 (TRPV1) receptor antagonist [1] cur-
rently being investigated for the treatment of overactive
bladder (OAB). OAB afﬂicts around 200 million people
worldwide and is characterized by the International Conti-
nence Society (ICS) as a syndrome encompassing urinary
urgency (with or without urge incontinence),usually with
frequency and nocturia in the absence of obvious patho-
logical or metabolic disease [2].The symptoms are sugges-
tive of detrusor overactivity but can occur due to other
forms of voiding or urinary dysfunction [3].
Currently available medications are usually antimusca-
rinic agents (oxybutynin,tolterodine and solifenacin [4–6],
etc.),with varying degrees of muscarinic receptor subtype
and/or organ selectivity [4,5,7–9].Antimuscarinics hold a
virtual monopoly in the therapy of urinary incontinence in
the western world [8]. Nevertheless, there is considerable
interest in developing alternative non-antimuscarinic
treatments, with the objective of avoiding the signiﬁcant
side effects associated with this class of drug (including
dry-mouth, nausea and constipation) which are believed
to contribute to poor long term compliance.
TRPV1 receptors are found in small myelinated
Ad-ﬁbres and sensory unmyelinated C-ﬁbres [10]. These
types of ﬁbres are located in the pelvic nerve afferents
which monitor the volume of the bladder and the ampli-
tude of bladder contractions. In a healthy bladder, these
C-ﬁbres are‘silent’and do not respond to bladder contrac-
tions. However, in the case of a person with OAB, spinal
cord injury or in situations where noxious stimuli are
involved, these C-ﬁbres become active and will convey a
signaltothespinalcordresultinginafeelingofurgencyto
urinate [11].To combat this overactivity,one possible strat-
egyistodesensitizetheC-ﬁbreafferents,soastoreduceor
eliminate the overactivity of the bladder without affecting
the voluntary bladder function. Hence, modulating the
TRPV1receptorsintheC-ﬁbrescouldbeaviabletreatment
for OAB.
Clinical evidence shows that instillation of the neuro-
toxicTRPV1 agonist capsaicin,into the bladder of subjects
with OAB, alleviates the OAB symptoms associated with
spinal cord injury and multiple sclerosis [12–15].This may
be explained by the observation that in some of these
subjects the micturition reﬂex was transduced mainly by
C-ﬁbres carrying the TRPV1 receptor at its nerve ending.
CapsaicinactivatestheTRPV1receptorcausingdepolariza-
tion and release of neurotransmitters from the nerve ter-
minals [10]. Sustained activation of the TRPV1 receptor
leads to desensitization, resulting in reduced neurotrans-
mitterrelease.Thisinturnalleviatesthesymptomsofover-
active bladder, a component of which is excessive release
of neurotransmitters in C-ﬁbres [16–18]. Consequently,
capsaicin instillation directly into the bladder, and the
resulting desensitization, is a useful treatment for OAB
[13–15]. It has therefore been postulated that a TRPV1
antagonistsuchasXEN-D0501maybeofclinicalbeneﬁtto
subjects with OAB of various origins, since an antagonist
would by-pass the need for desensitization (required
for efﬁcacy with an agonist such as capsaicin) and hence
result in an immediate, beneﬁcial effect on the bladder
overactivity.
XEN-D0501 has demonstrated subnanomolar potency
forTRPV1 receptors in human and rat recombinant cellular
systems and rat cultured dorsal root ganglion neurons
[unpublisheddata].SelectivityofXEN-D0501forTRPV1has
beenconﬁrmedusingpanelsofenzymes,ionchannelsand
G-protein coupled receptors. Further, XEN-D0501 has
demonstrated good efﬁcacy in disease models of OAB in
anaesthetized and conscious rats when administered
by both the intravenous and oral routes [manuscript in
preparation].
Two placebo-controlled clinical studies had been con-
ducted prior to the study discussed here [unpublished
data]. XEN-D0501 was administered to healthy male sub-
jects as an oral solution in both studies. The ﬁrst in man
study was initially planned to investigate single ascending
doses up to 160 mg XEN-D0501. Ultimately, only 5 and
10 mg XEN-D0501 were investigated. The 5 mg dose
appeared safe and well tolerated,but the 10 mg dose was
not considered to be well tolerated due to mild hyperther-
mia and a high incidence of oral adverse events (which
were thought to be due to TRPV1 antagonism by XEN-
D0501 at sensory nerve endings in the mouth).The study
was terminated without further dose escalation. The
second study investigated multiple ascending doses of 5
and10 mgtwicedailyXEN-D0501for12days.Thedecision
to include the 10 mg dose despite the apparent poor tol-
erationinthesingledosestudy,wasmadeonthebasisthat
the body temperature changes observed in the previous
study were not considered to be of clinical concern in a
trialsettingandinclusionofthisdosewouldenableassess-
ment of any attenuation of body temperature effects with
time (as had been observed in the literature [19]). Eight
subjects received the 5 mg twice daily dose, which
appeared safe and well tolerated. However the 10 mg
twice daily dose (administered to three subjects) was not
considered to be tolerated and the study was terminated
on the fourth day of dosing due to emerging adverse
events,notably one subject who had two episodes of tran-
sient urinary retention, both of which resolved spontane-
ously and without medical intervention. The two other
subjects who also received 10 mg twice daily XEN-D0501
were noted to have high post voiding residual volumes (as
assessed by non-invasive ultrasound) but did not experi-
ence any difﬁculties with voiding. Aural temperature was
assessed throughout the study and there was some evi-
dence that body temperature was higher following XEN-
D0501 compared with placebo. The magnitude of the
increase appeared to be 0.5°C to 1.5°C following XEN-
D0501 compared with placebo. However technical issues
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thevalidityofthedataandthis,coupledwithsmallsubject
numbers and limited dosing duration at the higher dose,
prevented any meaningful conclusions being drawn on
the effect of XEN-D0501 on body temperature.There were
no individual temperature measurements that were con-
sidered to be clinically signiﬁcant and none was reported
as an adverse event.
The primary objective of the study described herein
was to assess the safety,tolerability and pharmacokinetics
of multiple oral doses of XEN-D0501 given as a tablet for-
mulation to healthy male subjects aged 18 to 45 years.
Core body temperature (assessed using a validated telem-
etric physiological monitoring system) was a key safety
endpoint. Secondary objectives of the study were 1) to
investigatetheeffectoffoodonthepharmacokineticsofa
single oral dose of XEN-D0501 and 2) to investigate the
safety, tolerability and pharmacokinetics of a single oral
dose of XEN-D0501 in healthy male and female subjects
aged 46 to 65 years.
Methods
Subjects
The study population consisted of healthy male subjects
aged 18 to 45 years inclusive in part 1,and healthy male or
female subjects aged 46 to 65 years inclusive in part 2.
Female subjects were of non-childbearing potential (i.e.
post menopausal, or had undergone surgical sterilization
by hysterectomy or bilateral oophorectomy). All subjects
weighed between 50 and 100 kg, had a body mass index
between 18 and 32 kg m
-2 and were willing and able to
comply with study requirements. Exclusion criteria
included clinically signiﬁcant abnormal medical history or
physical examination including febrile illness within 1
week prior to the ﬁrst dose,clinically signiﬁcant history of
recurrent urinary tract infections, known prostatic hyper-
plasia or clinically signiﬁcant bladder outlet obstruction or
heart disease. There were also other standard exclusion
criteria concerning allergies, hypersensitivity, QTc interval,
blood pressure, laboratory abnormalities, pregnant or
nursing females, alcohol, nicotine and drug use. All sub-
jects gave written informed consent prior to participation
in the study and the study was conducted in accordance
with good clinical practice and with the ethical principles
outlined in the Declaration of Helsinki.The study was con-
ductedatLCGBioscience(Bourn,UK)andtheprotocolwas
approved by Welwyn Research Ethics Committee
appointedbyAAPEC,theAppointingAuthorityforPhase1
Ethics Committees in the UK.
Study design
Thestudywasconductedintwoparts.Part1wasadouble-
blind, randomized, placebo-controlled, two-way crossover
study involving three cohorts of 12 subjects.Each subject
received either XEN-D0501 or placebo in study period 1
followed by the alternative treatment in study period 2.A
washout period of at least 48 h was required between the
twostudyperiods.Subjectsremainedresidentatthestudy
site throughout each study period.XEN-D0501 or placebo
was administered twice daily for 13 days with a ﬁnal dose
on the morning of day 14 in each study period.The doses
of XEN-D0501 investigated were 1 mg twice daily (cohort
1), 2.5 mg twice daily (cohort 2) and 5 mg twice daily
(cohort 3).The cohorts were started sequentially.However
there was no formal safety review between cohorts and
they were allowed to overlap as the highest dose (5 mg
twice daily) had been studied previously and shown to be
well tolerated. Subjects were fasted for 10 h prior to each
morning dose and remained fasted until 4 h post dose on
days 1 and 14. On all other days, subjects were allowed
breakfast at least 1 h post dose. Standard meals were
allowed after at least 4 h post dose.Part 2 of the study was
an open-label, randomized, two-way crossover study
involving 16 subjects (eight male and eight female). Each
subject received a single dose of 5 mg XEN-D0501 on two
occasions separated by a minimum of 48 h. XEN-D0501
was administered either after a 10 h fast or within 30 min
after a high-fat breakfast.The breakfast was in accordance
with the FDA guidance on food–effect bioavailability
studies [20].
Pharmacokinetic methods
Blood samples for determination of XEN-D0501 plasma
concentrations were collected in part 1,prior to dosing on
eachstudydayandatintervalsupto12and24 hpostdose
ondays1and14respectively.Inpart2,bloodsampleswere
collected pre dose and up to 24 h post dose in each study
period. Plasma samples were analyzed using a validated
LC-MS/MS procedure. The overall method imprecision
values for the analysis of plasma quality control (QC)
samples were 3.8%, 3.8%, 2.5% and 3.5% at XEN-D0501
concentrations of 1.00, 3.00, 50.0 and 800 ng ml
-1 respec-
tively.Theaccuracy(relativeerror)oftheassayrangedfrom
-1.4% to +1.0% over the QC range.The calibration range
was1to1000 ng ml
-1XEN-D0501.Pharmacokineticparam-
eters were calculated using noncompartmental analysis
(WinNonlin™ version 5.2, model 200). Pharmacokinetic
parameters calculated on days 1 and 14 in part 1 included
maximum plasma concentration (Cmax), time to Cmax (tmax),
areaundertheconcentrationvs.timecurve(AUC)overthe
dosing interval t (AUC(0,t)). Terminal elimination half-life
(t1/2) and accumulation ratio (Rac; assessed as ratio of
AUC(0,t)onday14 : day1)werecalculatedonday14.Phar-
macokinetic parameters calculated in part 2 included Cmax,
tmax, AUC from zero to the last measured time point
(AUC(0,tlast),AUC from zero to inﬁnity (AUC(0,•)) and t1/2.
Safety
Safety assessments including adverse event (AE) monitor-
ing, physical examinations, 12-lead ECGs, vital signs
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ture), core body temperature and laboratory safety tests,
were conducted at intervals throughout the study. All
observed or reported AEs were recorded for all subjects
throughout the study. AEs were classiﬁed as mild,
moderateorsevereandtherelationshiptostudydrugwas
determined.
Aural temperature was measured using an appropri-
ately calibrated tympanic infrared thermometer (Braun
ThermoScan®). Single measurements were taken in the
same ear at each time point by trained study personnel
usingastandardizedtechnique.Subjectswerenotallowed
to use ear plugs or cover the ear within 20 min of each
measurement.
Corebodytemperaturewasmeasuredcontinuouslyfor
24 h on days 1, 2, 7 and 14 in part 1 using a Respironics
telemetric physiological monitoring system: Mini Mitter
with a Jonah™ ingestible core temperature capsule (Vital-
sense®) [21, 22]. Capsules were ingested 3 h prior to the
morningandeveningdoses(orequivalenttimeonday14)
to ensure continuous availability of temperature measure-
ments throughout the dosing period from capsules that
had already passed through the stomach. Data handing
rules were deﬁned and included exclusion of data trans-
mitted during the ﬁrst 3.5 h after capsule ingestion or
more than 24 h after ingestion.In addition,data collected
withinthelasthourpriortoexcretionofeachcapsulewere
excluded. Any data points below 30°C were excluded as
thesewereconsideredtobeerroneous.Validdatafromthe
morning capsule were used in the ﬁrst instance for each
day. However if the morning capsule was excreted before
the end of the 24 h window or if there were signiﬁcant
gaps in data transmission, then valid data from a subse-
quent capsule were used instead. On days 1, 2, 7 and 14
whencorebodytemperaturewasmeasured,subjectswere
not allowed to consume hot or chilled/frozen food or
drinks and all drinks and meals were served at room
temperature.
Statistical analysis
Noformalsamplesizecalculationswereperformedforthis
study and the subject numbers were considered to be suf-
ﬁcient to assess the safety,tolerability and pharmacokinet-
ics of XEN-D0501 at different dose levels. In addition, a
cohortsizeof12subjectsinpart1wasexpectedtoprovide
80% statistical power to conﬁrm a treatment difference of
0.5°C in body temperature (assuming a standard deviation
of 0.4). No assumptions were made prospectively on the
effect of food on the pharmacokinetics of XEN-D0501.The
sample size of 16 subjects in part 2 was estimated to
provide90%conﬁdenceintervals(CI)of0.131and0.189
on a natural log scale for AUC(0,tlast) and Cmax respectively
with 80% coverage probability. If no change in AUC(0,tlast)
and Cmax was observed, it was estimated that the 90% CIs
would be (88%,114%) and (83%,121%) respectively.
In part 1, the area under the core body temperature
(effect) time curve up to 12 h post-morning dosing
(AUEC(0,12 h)) was calculated for each subject and treat-
ment period, on days 1, 2, 7 and 14 using the trapezoidal
rule. AUEC(0,12 h) was evaluated as this was consistent
with the dosing interval and was the longest duration that
allowed direct comparison between treatment days,given
that an evening dose was administered on all days except
day 14. Minimum and maximum core body temperature
measurements over the same time period were also
assessed. These parameters were only calculated if there
were at least 10 h of valid data available during the 12 h
period.If the duration of valid recording was less than 10 h
thenthedatafromthatsubjectwereexcludedforthatday.
If the duration of valid recording was between 10 and 12 h
then AUEC(0,12 h) was normalized to 12 h by dividing the
subject’s AUEC by the duration of valid recording then
multiplying by 12 h.
AUEC(0,12 h) was analyzed by cohort using a repeated
measures mixed effects model with treatment, period,
sequence and study day as ﬁxed effects and subject as a
random effect.
Inpart2,ananalysisofvariance(ANOVA)wasperformed
on the log-transformed AUC(0,•), AUC(0,tlast) and Cmax
ﬁtting sequence and fed/fasting status as ﬁxed effects and
subject nested within sequence as a random effect.Ratios
between the means and 90% CIs for the differences are
presented.
Results
Subjects
A total of 52 subjects were enrolled and 50 subjects com-
pleted the study.Thirty-six subjects entered part 1 of the
study,buttwosubjectswerewithdrawnhavingcompleted
study period 1, but prior to dosing in period 2, due to
having tested positive for drugs of abuse.One of the sub-
jectsreceivedplaceboinperiod1andwaswithdrawnprior
to receiving 2.5 mg XEN-D0501, whilst the other received
5 mg XEN-D0501 in period 1 and was withdrawn prior to
receiving placebo in period 2. Sixteen subjects entered
part 2 of the study and all completed.All subjects in part 1
weremalesaged20to44years(mean31.7years).Ofthe16
subjects who entered part 2 of the study,eight were male
andeightwerefemaleandthesubjectswereaged46to64
years (mean 55.0 years).
PK results
XEN-D0501 was rapidly absorbed with tmax occurring
within 0.5 to 4 h following single and multiple dosing in
part 1 (Table 1, Figure 1). XEN-D0501 appeared to exhibit
non-proportional pharmacokinetics, with exposure (geo-
metric mean Cmax and AUC(0,t)) increasing 3.5-fold (day 1)
and 2.8-fold (day 14) over the ﬁve-fold dose range. The
pharmacokineticsofXEN-D0501exhibitedmoderateinter-
P.Round et al.
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variation (CV) for Cmax and AUC parameters ranging from
30 to 50%. Plasma XEN-D0501 concentrations generally
declined in a monoexponential manner with t1/2 values of
approximately 3–4 h. Accumulation ratios based on Cmax
and AUC(0,t) were comparable across the dose range and
suggested minimal accumulation of XEN-D0501 with
twice daily dosing.Visual assessment of individual trough
concentrations (data not shown) suggested steady-state
was achieved within 1 to 2 days of dosing.
Mean Cmax was lower and occurred later when XEN-
D0501 was administered in the fed compared with the
fasted state.The statistical analysis (Table 2) shows a food
effect (mainly on Cmax) but this effect was considered to be
small and unlikely to be clinically relevant.In addition,the
Cmaxand AUC(0,tlast) data were affected by one subject who
had notably lower XEN-D0501 plasma concentrations in
thefedstatecomparedwithalloftheothersubjects.Itwas
also not possible to calculate AUC(0,•) in this subject
during the fed period. Re-running the statistical analysis
without this outlying subject had no relevant effect on the
ratio and 90% CIs for AUC(0,•),but changed the ratio and
90%CIsforAUC(0,tlast)to102.06(95.40,109.19)andforCmax
to 91.65 (76.23,110.19).
Safety
There were no serious or severe AEs in this study and the
majority of AEs were classed as mild in nature.A summary
of the most common AEs,deﬁned as any AE that occurred
in more than one subject in any treatment group, is pre-
sented in Table 3. The most common AEs in part 1 were
headache, feeling cold, dizziness, oropharyngeal pain and
feeling hot.With the exception of oropharyngeal pain,the
othermostcommonAEswereallreportedincohorts2and
3 (2.5 and 5 mg BID XEN-D0501), and predominantly fol-
lowing XEN-D0501 rather than placebo. They were also
predominantly considered treatment-related. The inci-
dence of other individual AEs was generally low,although
someAEscouldbegroupedintosimilarorrelatedterms.In
particular there were a variety of AEs associated with per-
ception of,or response to,body temperature,e.g.hot ﬂush,
burning sensation, feeling hot, pyrexia, feeling of body
temperature change, feeling cold, chills, peripheral cold-
ness, night sweats, hyperhydrosis and cold sweat. All of
these terms were described as mild,with the exception of
burning sensation (in head) which was described as mod-
erate.Takenasagroup,thereappearedtobeadoserelated
trend to increased reporting with increased XEN-D0501
dose. None of the subjects reported any difﬁculties or
changes in their ability to urinate.
The AE proﬁle in part 2 was similar to part 1 with the
mostcommonAEsbeingdysgeusia,feelingcold,headache
and oral paraesthesia.
Table 1
Summary of XEN-D0501 pharmacokinetic parameters
Parameter Day
XEN-D0501 dose group
1 mg twice daily 2.5 mg twice daily 5 mg twice daily
(n = 12) (n = 11) (n = 12)
tmax (h) median (range) 1 1.27 (0.50–3.00) 1.50 (0.60–4.00) 1.50 (1.00–2.00)
14 1.00 (0.50–3.00) 1.00 (0.50–3.00) 2.02 (0.72–4.00)
Cmax (ng ml-1) mean (CV%)† 1 14.9 (36%) 26.8 (31%) 51.6 (34%)
14 17.6 (34%) 31.4 (36%) 49.8 (38%)
AUC(0,t) (ng ml-1 h) mean (CV%)† 1 56.0 (46%) 112 (43%) 198 (47%)
14 73.2 (47%) 136 (48%) 248 (52%)
t1/2 (h) mean (CV%)† 14 3.18 (44%) 2.89 (63%) 4.12 (51%)
Rac (AUC(0,t)) mean (CV%)† 14 1.31 (19%) 1.22 (18%) 1.25 (16%)
Rac (Cmax) mean (CV%)† 14 1.18 (37%) 1.17 (20%) 0.97 (20%)
†Unadjusted geometric mean.
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(),1 mg XEN-D0501 – day 14 (),2.5 mg XEN-D0501 – day 1 (),2.5 mg
XEN-D0501 – day 14 (),5 mg XEN-D0501 – day 1 (),5 mgXEN-D0501–
d a y1 4( )
Safety and PK of XEN-D0501
Br J Clin Pharmacol / 72:6 / 925Adiurnalvariationinmeancorebodytemperaturewas
observed in all subjects with all treatments,with tempera-
tures generally peaking at approximately 6 h after the
morning dose (Figure 2). Visual inspection of mean core
body temperatures, suggested that they were generally
higher following XEN-D0501 compared with placebo at all
time points, with the greatest differences generally
observed over the 0 to 8 h following each dose (morning
and evening). There was a dose-dependent increase in
mean core body temperature; the maximum core body
temperature values following placebo ranged from 37.03
to 37.99°C,whilst those following XEN-D0501 ranged from
37.23 to 39.07°C (1 mg twice daily), 37.43 to 38.35°C
(2.5 mg twice daily) and 37.23 to 38.82°C (5 mg twice
daily). No formal statistical analyses were conducted.
However the differences from placebo in mean maximum
core body temperature (Table 4) following XEN-D0501 on
day 1 were 0.22°C (1 mg twice daily),0.50°C (2.5 mg twice
daily) and 0.74°C (5 mg twice daily).By day 14,these differ-
ences had reduced to 0.15°C (1 mg twice daily), 0.11°C
(2.5 mgtwicedaily)and0.30°C(5 mgtwicedaily)(Table 4).
Visual assessment of the core body temperature proﬁles
suggests that there was no residual effect of XEN-D0501
on core body temperature by approximately 12 h after the
lastdoseonday14.Maximumcorebodytemperatureover
the 12 h after the morning dose for each subject was
assessed on each measurement day and for each treat-
ment.ThestatisticalanalysisoftheAUEC(0,12 h)datadem-
onstrated a statistically signiﬁcant difference (P < 0.05)
between XEN-D0501 and placebo on all days except for
day 7 following 1 mg twice daily XEN-D0501; the magni-
tude of the difference decreased with time (Table 5).
Table 2
Summary of XEN-D0501 pharmacokinetic parameters in fasted and fed conditions
Parameter
5 mg XEN-D0501 fasted 5 mg XEN-D0501 fed Ratio of adjusted least
(n = 16) (n = 16) squares means (90% CI)
tmax (h) median (range) 1.50 (0.50–3.00) 3.00 (1.00–6.00) NA
Cmax (ng ml-1) mean (CV%)† 77.9 (34%) 62.8 (68%) 80.62 (58.39, 111.31)
AUC(0,tlast) (ng ml-1 h) mean (CV%)† 347 (45%) 316 (67%) 91.08 (70.89, 117.02)
AUC(0,•) (ng ml-1 h) mean (CV%)† 361 (47%) 328 (70%) 100.98 (93.99, 108.48)
t1/2 (h) mean (CV%)† 4.57 (39%) 3.70 (42%) NA
†Unadjusted geometric mean.
Table 3
Summary of the most common AEs†
Cohort 1 Cohort 2 Cohort 3
XEN-D0501
Placebo
XEN-D0501
Placebo
XEN-D0501
Placebo 1 mg twice daily 2.5 mg twice daily 5 mg twice daily
Total subjects 12 12 11 12 12 11
Subjects with AEs 86 1 0 8 1 17
AE (Preferred term)
Headache 0 0 4 (4) 1 (1) 7 (7) 4 (3)
Feeling cold 0 0 3 (3) 0 5 (5) 0
Dizziness 0 0 1 (1) 0 4 (4) 2 (0)
Oropharyngeal pain 1 (0) 1 (0) 1 (0) 2 (0) 0 2 (0)
Feeling hot 0 0 3 (3) 0 1 (1) 1 (1)
Abnormal dreams 0 0 1 (0) 2 (0) 0 1 (0)
Nasal congestion 0 1 (0) 1 (0) 2 (0) 0 0
Nausea 0 0 0 0 2 (2) 2 (1)
Night sweats 1 (1) 0 1 (1) 0 2 (2) 0
Paraesthesia 0 0 1 (1) 0 3 (3) 0
Dry throat 0 0 3 (2) 0 0 0
Dysgeusia 0 0 0 0 3 (3) 0
Hot ﬂush 0 0 0 0 3 (3) 0
Nasal pharyngitis 0 2 (0) 1 (0) 0 0 0
Burning sensation 0 0 0 0 2 (2) 0
Erythema 0 0 0 0 2 (0) 0
Hyperhidrosis 0 0 0 0 2 (2) 0
†Most common is deﬁned as any adverse event that occurred in more than one subject in any treatment group. Values are the number of subjects with all causality AEs
(treatment-related AEs).
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Figure 2
Mean core body temperature.1 mg twice daily XEN-D0501 ( ),2.5 mg twice daily XEN-D0501 ( ),5 mg twice daily XEN-D0501 ( ),Cohort 1 placebo ( ),
Cohort 2 placebo ( ),Cohort 3 placebo ( )
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study and no subjects had any measurements that were
deemed to be clinically signiﬁcant.Aural temperatures fol-
lowing placebo ranged from 35.2°C to 38.0°C,whilst those
following XEN-D0501 ranged from 35.7°C to 38.4 (1 mg
twice daily), 35.6°C to 37.7°C (2.5 mg twice daily) and
35.5°C to 38.2°C (5 mg twice daily). In general, the aural
temperature measurements were slightly lower than the
core body temperature measurements, although the
trends over time and differences between XEN-D0501
doses and placebo were similar for both measurements
(Figure 3).
There were no clinically relevant ﬁndings or changes in
any of the other safety parameters.
Discussion
XEN-D0501 had previously been administered to healthy
malesubjectsintwophase1studies,assingleandmultiple
(twice daily) doses (5 and 10 mg). In each study the 5 mg
dose appeared to be safe and was well tolerated, but the
10 mg dose was found to induce mild hyperthermia and
oral hypoaesthesia (thought to be associated with the
Table 4
Summary of core body temperature parameters
Parameter†
Cohort 1 Cohort 2 Cohort 3
n = 12 n = 12 n = 12
1 mg twice daily
Placebo
2.5 mg twice daily
Placebo
5 mg twice daily
Placebo XEN-D0501 XEN-D0501 XEN-D0501
AUEC(0,12 h) (°C h)
Day 1
n 11 10 11 11 10 10
Mean 447 443 450 445 453 444
SD 2.1 2.0 2.4 1.5 3.7 1.5
Min, max 444, 451 440, 447 447, 454 442, 446 446, 461 440, 446
Day 2
n 7 11 8 11 10 9
Mean 450 445 450 444 450 444
SD 4.8 1.0 1.6 1.5 2.5 1.3
Min, max 446, 460 444, 446 448, 452 442, 447 447, 456 442, 446
Day 7
n 8 9 11 10 11 8
Mean 446 446 448 446 448 444
SD 1.4 1.8 2.1 1.4 1.7 2.0
Min, max 444, 448 444, 450 444, 452 443, 448 446, 451 440, 447
Day 14
n 10 9 10 11 10 10
Mean 447 445 448 445 447 444
SD 1.6 1.9 1.8 1.9 2.1 1.4
Min, max 444, 449 443, 448 445, 451 441, 447 443, 450 441, 446
Maximum temperature (°C)
Day 1
n 11 10 11 11 10 10
Mean 37.64 37.42 37.90 37.40 38.16 37.42
SD 0.21 0.13 0.19 0.14 0.32 0.16
Min, max 37.23, 37.98 37.21, 37.58 37.66, 38.16 37.06, 37.55 37.60, 38.82 37.16, 37.73
Day 2
n 7 11 8 11 10 9
Mean 37.95 37.44 37.91 37.43 37.91 37.46
SD 0.51 0.13 0.23 0.15 0.27 0.19
Min, max 37.61, 39.07 37.23, 37.70 37.59, 38.27 37.24, 37.71 37.58, 38.49 37.16, 37.72
Day 7
n 8 9 11 10 11 8
Mean 37.54 37.60 37.77 37.56 37.74 37.45
SD 0.18 0.14 0.29 0.21 0.18 0.22
Min, max 37.29, 37.85 37.40, 37.90 37.46, 38.35 37.24, 37.88 37.44, 38.13 37.19, 37.82
Day 14
n 10 9 10 11 10 10
Mean 37.59 37.44 37.70 37.59 37.69 37.39
SD 0.20 0.23 0.26 0.25 0.25 0.18
Min, max 37.32, 37.90 37.21, 37.91 37.43, 38.12 37.13, 37.99 37.23, 38.03 37.03, 37.64
†Measured over the 0–12 h after the morning dose of XEN-D0501 or placebo.
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urinary retention following repeated dosing in one
subject. Whilst urinary retention in healthy subjects is
clearly undesirable,coupled with the raised residual urine
volumes observed in the other two subjects who received
10 mg twice daily XEN-D0501, it does suggest that XEN-
D0501 is capable of having an appropriate effect on the
bladder for the proposed indication of OAB.
The involvement of TRPV1 in thermoregulation has
been known for many years [18, 23, 24] and the more
recent interest in TRPV1 antagonists for various therapeu-
tic indications has led to the testing of many compounds
(mainly for pain indications) some of which have been
noted to cause increases in body temperature either in
animals and/or man [25, 26]. This effect has also been
showntoattenuatewithmultipledosingofTRPV1antago-
nists [19]. The magnitude of the changes in temperature
also appears to be compound dependent with some com-
pounds producing marked hyperthermia [19,26],whereas
others, such as capsazepine, SB-366791 and AS1928370,
have been reported to have no apparent effect on body
temperature (in rats) [27,28].
In the light of the potential for XEN-D0501 to increase
body temperature, particular attention was paid to moni-
toring body temperature in this study. The ingestion of
telemetric VitalSense® capsules at speciﬁed intervals on
days 1,2,7,and 14 allowed continuous monitoring of core
body temperature for 24–48 h. The two-way crossover
design of the study also allowed for within-subject com-
parisons of core body temperature. The data suggested
thatXEN-D0501causedadose-dependentincreaseincore
body temperature which was greatest on the ﬁrst day of
dosing but rapidly attenuated thereafter. Despite the
attenuation of effect, core body temperatures did remain
higher following XEN-D0501 compared with placebo
throughout the dosing period. There was no discernable
effectofXEN-D0501oncorebodytemperaturebyapproxi-
mately 12 h after the ﬁnal dose,presumably reﬂecting the
declining plasma XEN-D0501 concentrations.The effect of
XEN-D0501 on body temperature was also apparent and
adequately characterized using aural (tympanic) measure-
ments, conﬁrming that this method is appropriate for
ongoing safety assessments in the clinic.
The mechanism for TRPV1-mediated hyperthermia is
still to be fully proven,but an increasing body of evidence
suggests that these effects are driven by block of afferent
ﬁbres innervating the abdominal viscera [29].Tonic activa-
tionofTRPV1channelsinthevisceraisbelievedtoregulate
thermogenesisandskinvasoconstrictionprocesseswhich,
if disturbed through visceral and/or peripheral inhibition
of TRPV1, could give rise to a hyperthermic response. It is
quite clear that the hyperthermic effects ofTRPV1 antago-
nists are not a central effect through regulation of hypo-
thalamic TRPV1 channels involved in body temperature
control, and nor are they a thermosensor response
through inhibition of heat-activatedTRPV1 [29].There was
no evidence from review of standard laboratory safety
parameters of concomitant inﬂammatory processes asso-
ciated with the changes in body temperature following
XEN-D0501.
This study demonstrated that repeat dosing of XEN-
D0501 up to 5 mg twice daily appeared safe and well tol-
erated. XEN-D0501 was also administered as single doses
(5 mg) to males and females aged 46 to 65 years (a popu-
lation considered to more closely reﬂect the target OAB
population), and whilst no placebo control was available
for this population, there was no evidence of any signiﬁ-
cant differences in the safety and tolerability proﬁle com-
pared with the younger males.
The pharmacokinetic data suggest that XEN-D0501
exposure (Cmax and AUC) increases less than dose propor-
tionally.Whilst it should be noted that this study was not
designednorformallyanalyzedtoassessdoseproportion-
ality, the data are consistent with previous data from the
single dose ﬁrst-in-human study and data observed in rats
and dogs [unpublished data]. The subproportionality is
Table 5
Summary of repeated measures analysis of core body temperature AUEC(0,12 h)
XEN-D501 vs. placebo
Day 1 Day 2 Day 7 Day 14
Cohort 1: 1 mg twice daily vs. placebo
Treatment difference 3.39 4.68 -0.29 1.80
95% CI 1.80, 4.98 2.90, 6.45 -2.08, 1.51 0.10, 3.50
P value <0.0001 <0.0001 0.75 0.04
Cohort 2: 2.5 mg twice daily vs. placebo
Treatment difference 5.70 5.65 2.29 2.22
95% CI 4.45, 6.95 4.27, 7.04 1.01, 3.56 0.94, 3.51
P value <0.0001 <0.0001 0.0006 0.0010
Cohort 3: 5 mg twice daily vs. placebo
Treatment difference 8.86 6.12 3.75 2.92
95% CI 7.50, 10.22 4.73, 7.51 2.35, 5.15 1.56, 4.28
P value <0.0001 <0.0001 <0.0001 <0.0001
Safety and PK of XEN-D0501
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probably caused by the low solubility of the compound
(2 mg l
-1 in pH 7 buffer [unpublished data]). In vitro data
from studies using recombinant cytochrome P450 (CYP)
isoforms, human liver microsomes and human hepato-
cytes,suggest that XEN-D0501 is primarily metabolized by
CYP3A4, and does not inhibit or induce this enzyme at
clinically relevant concentrations [unpublished data]. The
terminal half-life of XEN-D0501 did not appear to change
with dose.Data from part 2 of the study suggest that XEN-
D0501 can be given without regard for food, although
there was one outlier who had very low XEN-D0501 expo-
sures following administration with food. The reason for
this apparent discrepancy with the other subjects’ data
and its clinical relevance is not known.
OverallthedatasuggestthatXEN-D0501isapromising
TRPV1 antagonist that has potential for the treatment of
OAB.
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